Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Amid the difficulties created by the COVID-19 pandemic, synthetic cannabinoid company Botanix Pharmaceuticals (ASX: BOT) unveiled an operational boost in the form of support from the US FDA to fast track its first antibacterial product BTX 1801.
Earlier today, the company announced that the FDA’s Office of Antimicrobial Products had granted BTX 1801 – a treatment to prevent post-surgical infections – what’s known as qualified infectious disease product (QIDP) status which means Botanix can receive a variety of incentives as part of its drug development program.
https://botanixpharma.com/wp-content/uploads/News_2_FDA_Grant_BTX1801_800x800-e1594359817975.jpg800800administrator/wp-content/uploads/botanix-logo.pngadministrator2020-04-24 09:57:542023-03-13 21:17:20Botanix Pharmaceuticals receives FDA grant for antibacterial product BTX 1801
Botanix Pharmaceuticals Limited (ASX: BOT) today provided investors with an update on its suite of cannabis-derived clinical trials that target dermatological and antimicrobial conditions. In addition to this, the company has provided its roadmap, outlining how Botanix will be moving forward amid the COVID-19 crisis.
/wp-content/uploads/botanix-logo.png00administrator/wp-content/uploads/botanix-logo.pngadministrator2020-03-13 10:09:572023-03-13 21:17:21Botanix Pharmaceuticals plans new study into antimicrobial platform and BTX 1801
/wp-content/uploads/botanix-logo.png00administrator/wp-content/uploads/botanix-logo.pngadministrator2020-03-13 10:07:402023-03-13 21:17:21Botanix’s cannabis drug kills bacteria in minutes
/wp-content/uploads/botanix-logo.png00administrator/wp-content/uploads/botanix-logo.pngadministrator2020-03-04 10:24:262023-03-13 21:17:21Botanix achieved significant results with Acne drug
Botanix Pharmaceuticals receives FDA grant for antibacterial product BTX 1801
/in Featured, Latest News /by administratorAmid the difficulties created by the COVID-19 pandemic, synthetic cannabinoid company Botanix Pharmaceuticals (ASX: BOT) unveiled an operational boost in the form of support from the US FDA to fast track its first antibacterial product BTX 1801.
Earlier today, the company announced that the FDA’s Office of Antimicrobial Products had granted BTX 1801 – a treatment to prevent post-surgical infections – what’s known as qualified infectious disease product (QIDP) status which means Botanix can receive a variety of incentives as part of its drug development program.
Click HERE to read the article on SmallCaps.
Botanix reshuffles business priorities
/in Featured, Latest News /by administratorBotanix Pharmaceuticals Limited (ASX: BOT) today provided investors with an update on its suite of cannabis-derived clinical trials that target dermatological and antimicrobial conditions. In addition to this, the company has provided its roadmap, outlining how Botanix will be moving forward amid the COVID-19 crisis.
Click HERE to read the article on The Green Fund.
Botanix Pharmaceuticals (ASX:BOT) launches Phase 2 BTX 1801 study for SSIs
/in Latest News /by administratorBotanix Pharmaceuticals plans new study into antimicrobial platform and BTX 1801
/in Latest News /by administratorBotanix’s cannabis drug kills bacteria in minutes
/in Latest News /by administratorBotanix achieved significant results with Acne drug
/in Latest News /by administrator